Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

被引：1762

作者：

Neuschwander-Tetri, Brent A. ^{[1
]}

Loomba, Rohit ^{[2
]}

Sanyal, Arun J. ^{[3
]}

Lavine, Joel E. ^{[4
]}

Van Natta, Mark L. ^{[5
]}

Abdelmalek, Manal F. ^{[6
]}

Chalasani, Naga ^{[7
]}

Dasarathy, Srinivasan ^{[11
]}

Diehl, Anna Mae ^{[6
]}

Hameed, Bilal ^{[9
]}

Kowdley, Kris V. ^{[10
]}

McCullough, Arthur ^{[8
]}

Terrault, Norah ^{[9
]}

Clark, Jeanne M. ^{[5
]}

Tonascia, James ^{[5
]}

Brunt, Elizabeth M. ^{[12
]}

Kleiner, David E. ^{[13
]}

Doo, Edward ^{[14
]}

机构：

[1] St Louis Univ, St Louis, MO 63110 USA

[2] Univ Calif San Diego, La Jolla, CA 92093 USA

[3] Virginia Commonwealth Univ, Richmond, VA USA

[4] Columbia Univ, New York, NY USA

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Duke Univ, Durham, NC USA

[7] Indiana Univ, Indianapolis, IN 46204 USA

[8] Cleveland Clin, Cleveland, OH 44106 USA

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[11] Case Western Reserve Univ, Cleveland, OH 44106 USA

[12] Washington Univ, St Louis, MO USA

[13] NCI, Bethesda, MD 20892 USA

[14] NIDDK, Bethesda, MD 20892 USA

来源：

LANCET | 2015年 / 385卷 / 9972期

关键词：

FATTY LIVER-DISEASE; BILE-ACIDS; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; FXR; AGONIST; THERAPY; NAFLD; NASH; RATS;

D O I：

10.1016/S0140-6736(14)61933-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. Methods We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic, non-alcoholic steatohepatitis to assess treatment with obeticholic acid given orally (25 mg daily) or placebo for 72 weeks. Patients were randomly assigned 1: 1 using a computer-generated, centrally administered procedure, stratified by clinical centre and diabetes status. The primary outcome measure was improvement in centrally scored liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least 2 points without worsening of fibrosis from baseline to the end of treatment. A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before end-of-treatment (72 weeks) biopsies supported the decision to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3). A planned interim analysis of the primary outcome showed improved efficacy of obeticholic acid (p=0 . 0024) and supported a decision not to do end-of- treatment biopsies and end treatment early in 64 patients, but to continue the trial to obtain the 24-week post-treatment measures. Analyses were done by intention-to-treat. This trial was registered with ClinicalTrials.gov, number NCT01265498. Findings Between March 16, 2011, and Dec 3, 2012, 141 patients were randomly assigned to receive obeticholic acid and 142 to placebo. 50 (45%) of 110 patients in the obeticholic acid group who were meant to have biopsies at baseline and 72 weeks had improved liver histology compared with 23 (21%) of 109 such patients in the placebo group (relative risk 1 . 9, 95% CI 1 . 3 to 2 . 8; p=0 . 0002). 33 (23%) of 141 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo group. Interpretation Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarifi cation.

引用

页码：956 / 965

页数：10

共 30 条

[1] Liver Transplantation for Nonalcoholic Steatohepatitis The New Epidemic [J].